Skip to main content
. 2017 Oct 5;12:43. doi: 10.1186/s13011-017-0127-0

Table 5.

Univariate linear regression analysis for associations between BLL and clinical symptoms, type of substance, route of use, duration of use or daily quantity of consumption

Variable B (SE) 95% CI t p-value
Type of substance (opium) 0.36 (0.22) −0.1, 0.79 1.67 0.09
Route of use (oral route) 0.23 (0.16) −0.1, 0.55 1.44 0.15
Duration of use 0.009 (0.01) −0.02, 0.04 0.63 0.53
Daily quantity of consumption 0.08 (0.26) −0.44, 0.60 0.29 0.77
Abdominal pain (yes) 0.98 (0.25) 0.85, 1.05 1.89 0.03
Constipation (yes) 0.13 (0.31) −0.09, 0.68 0.75 0.68
Arthralgia (yes) 0.05 (0.33) −0.05, 0.24 0.23 0.88
Myalgia (yes) 1.16 (0.34) 1.08, 1.38 2.12 0.006
Anorexia (yes) 0.58 (0.30) 0.34,0.72 1.79 0.04
Nausea (yes) 0.32 (0.33) −0.08, 0.65 0.99 0.33
Peripheral neuropathy (yes) 0.71 (0.69) −0.1, 0.98 1.12 0.30
Weakness (yes) 0.19 (0.33) −0.05, 0.85 0.61 0.55
Insomnia (yes) 0.21 (0.28) −0.04, 0.83 0.77 0.44

F = 1.98, dfb = 13, dfw = 236, p-value = 0.04